Search clinical trials for: Sotagliflozin (SAR439954)

Total 65 results

Sanofi

Completed

Sotagliflozin Bioequivalence Study

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects

Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Type 2 Diabetes Mellitus

United States, Canada, Mexico
Lexicon Pharmaceuticals
Sanofi

Terminated

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

Cardiac Failure Aggravated

United States, Canada, Netherlands
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Heart Failure | Type 2 Diabetes Mellitus

Belgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
Sanofi

Completed

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Type 2 Diabetes Mellitus | Healthy Subjects

United States
Sanofi

Completed

Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3

United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Sanofi

Completed

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Breast Cancer | Healthy Volunteers

United Kingdom
Sanofi

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects

Diabetes Mellitus

United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control (SOTA-CKD4)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4

United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Type 2 Diabetes Mellitus

United States, Canada, Hungary, Slovakia
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Type 2 Diabetes Mellitus

China
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Type 2 Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Type 2 Diabetes Mellitus

United States, Bulgaria, Estonia, Hungary, Korea, Republic of, Poland, Romania, Slovakia, Ukraine, United Kingdom
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
Sanofi

Completed

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Diabetes Mellitus | Healthy Subjects

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Sanofi

Completed

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Type 2 Diabetes Mellitus | Healthy Subjects

United Kingdom
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents (SOTA-INS)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom
Joshua S. Jacobs

Unknown

Effect of Reslizumab in Chronic Rhinosinusitis

Sinusitis

United States
Sanofi

Active, not recruiting

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2) (AMEERA-2)

Breast Cancer

Japan
University of Nottingham

Completed

Effects of FODMAPs on Small Bowel Water Content: an MRI Study (FODMAPs)

Healthy

United Kingdom
Sanofi

Recruiting

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta

United States, Australia, Canada, France
Genzyme, a Sanofi Company

Completed

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Hemophilia A | Hemophilia B

Bulgaria, United States, United Kingdom, Russian Federation, Switzerland
Genzyme, a Sanofi Company

Active, not recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Hemophilia

Canada, Italy, Turkey, Spain, United States, India
Daewoong Pharmaceutical Co. LTD.

Recruiting

Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

Gastroesophageal Reflux Disease

Korea, Republic of
Sanofi

Completed

Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects

Diabetes Mellitus

France
University Medical Center Groningen
Juvenile Diabetes Research Foundation; Lexicon Pharmaceuticals

Not yet recruiting

Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation (ASPIRE)

Type 1 Diabetes Mellitus With Diabetic Nephropathy

Netherlands, United States, Canada, Denmark, Finland
Sanofi

Terminated

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Malignant Solid Tumor

France, Spain, Australia, Belgium, Italy, United Kingdom, Taiwan, Estonia, Netherlands, Korea, Republic of, United States, Canada, Germany
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Recruiting

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG) (CEMI-LUNG)

Non-small Cell Lung Cancer

Germany, Austria, France
Sanofi
Regeneron Pharmaceuticals

Completed

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (TOSCA)

Cancer/Squamous Cell Carcinoma of Skin

France
Lexicon Pharmaceuticals

Unknown

Oral Contraceptive DDI Study

Healthy

United States
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)

Type 2 Diabetes Mellitus

Estonia, Spain, Ukraine, Italy, Germany, Canada, Mexico, United States, Argentina, Bulgaria, Chile, Denmark, Finland, Hungary, India, Korea, Republic of, Latvia, Lithuania, Norway, Peru, Poland, Romania, Russian Federation, Serbia, Slov... and more
Sanofi

Recruiting

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Hemophilia A

Taiwan
Hanmi Pharmaceutical Company Limited
Sanofi

Completed

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise (AMPLITUDE-M)

Type 2 Diabetes Mellitus

United States, Germany, Poland, Ukraine, United Kingdom
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (AMPLITUDE-L)

Type 2 Diabetes Mellitus

Korea, Republic of, United States, China
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin

Diabetes Mellitus

France
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin (AMPLITUDE-D)

Type 2 Diabetes Mellitus

United States, Poland, Ukraine, Hungary
Lexicon Pharmaceuticals

Completed

Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Healthy | Renal Impairment

United States
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (AMPLITUDE-S)

Type 2 Diabetes Mellitus

United States, China, Taiwan
Juan Badimon

Recruiting

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Heart Failure With Preserved Ejection Fraction

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States

3

Subscribe